Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Ann Surg. 2021 Aug 1;274(2):e134-e142. doi: 10.1097/SLA.0000000000003503.
To test the hypothesis that complete, tumor-free resection at the pancreatic neck, achieved either en-bloc or non-en-bloc (ie, revision based on intraoperative frozen section [FS] analysis), is associated with improved survival as compared with incomplete resection (IR) in pancreatic ductal adenocarcinoma.
Given the likely systemic nature of pancreatic ductal adenocarcinoma, the oncologic benefit of achieving a histologically complete local resection, particularly through revision of a positive intraoperative FS at the pancreatic neck, remains controversial.
Clinicopathologic and treatment data were reviewed for 986 consecutive patients with ductal adenocarcinoma at the head, neck, or uncinate process of the pancreas who underwent open pancreatectomy as well as intraoperative FS analysis between 1998 and 2012 at Massachusetts General Hospital and between 1998 and 2013 at the University of Verona. Overall survival (OS) and perioperative morbidity and mortality were compared across 3 groups: complete resection achieved en-bloc (CR-EB), complete resection achieved non-en-bloc (CR-NEB), and IR.
The CR-EB cohort comprised 749 (76%) patients, CR-NEB 159 patients (16%), and IR 78 patients (8%). Other than a higher incidence of vascular resection among CR-NEB and IR patients, no demographic, pathologic (eg, tumor grade, lymph node positivity, superior mesenteric artery involvement), or treatment factors (eg, neoadjuvant and adjuvant therapy use) differed between the groups. Median OS was significantly higher in patients with CR-EB (28 mo, P = 0.01) and CR-NEB resections (24 mo, P = 0.02) as compared with patients with IR resections (19 mo). After adjusting for clinicopathologic and treatment characteristics, CR-EB and CR-NEB margin status were found to be independent predictors of improved OS (relative to IR, CR-EB hazard ratio [HR] 0.65, 95% confidence interval [CI] 0.49-0.86; CR-NEB HR 0.69, 95% CI 0.50-0.96). There were no intergroup differences in perioperative morbidity and mortality, including rates of pancreatic fistula.
For patients with ductal adenocarcinoma at the head, neck, or uncinate process of the pancreas undergoing pancreatectomy, complete tumor extirpation via either en-bloc or non-en-bloc complete resection based on FS analysis is associated with improved OS, without an associated increased perioperative morbidity or mortality.
检验下述假说,即在胰腺颈部行整块或非整块(即根据术中冷冻切片[FS]分析进行修正)肿瘤无残留的完全切除术与不完全切除术(IR)相比,与胰腺导管腺癌患者的生存改善相关。
鉴于胰腺导管腺癌可能具有全身性,通过修正胰腺颈部阳性术中 FS 来实现局部组织学完全切除的肿瘤学获益仍存在争议。
回顾性分析了 1998 年至 2012 年在马萨诸塞州综合医院以及 1998 年至 2013 年在维罗纳大学接受开放胰腺切除术并进行术中 FS 分析的 986 例头颈部或钩突部胰腺导管腺癌连续患者的临床病理和治疗数据。比较 3 组患者的总生存(OS)和围手术期发病率和死亡率:整块切除(CR-EB)、非整块切除(CR-NEB)和 IR。
CR-EB 组 749 例(76%),CR-NEB 组 159 例(16%),IR 组 78 例(8%)。除了 CR-NEB 和 IR 患者血管切除的发生率较高外,各组之间的人口统计学、病理学(例如肿瘤分级、淋巴结阳性、肠系膜上动脉受累)和治疗因素(例如新辅助和辅助治疗的使用)无显著差异。与 IR 切除患者相比,CR-EB(28 个月,P=0.01)和 CR-NEB 切除患者(24 个月,P=0.02)的中位 OS 明显更高。在调整临床病理和治疗特征后,CR-EB 和 CR-NEB 的切缘状态被发现是 OS 改善的独立预测因素(与 IR 相比,CR-EB 的 HR 为 0.65,95%CI 为 0.49-0.86;CR-NEB 的 HR 为 0.69,95%CI 为 0.50-0.96)。围手术期发病率和死亡率,包括胰瘘发生率,各组间无差异。
对于接受胰腺切除术的头、颈或钩突部胰腺导管腺癌患者,基于 FS 分析的整块或非整块(即根据术中 FS 分析进行修正)完整肿瘤切除与 OS 改善相关,而围手术期发病率和死亡率无增加。